Santhera Pharmaceuticals Gains EU Boost for AGAMREE Expansion
PRATTELN, Switzerland, April 27, 2026 Santhera Pharmaceuticals has achieved a significant regulatory milestone with the European Medicines Agency’s (EMA)...
rare diseases
Advertisement
Novartis Itvisma Gains CHMP Boost for SMA Therapy
Basel, Switzerland | April 24, 2026 In a major breakthrough for rare disease treatment, Novartis has received a positive...
Polaryx Therapeutics Secures FDA Fast Track for PLX-200 in Rare Diseases
Paramus, New Jersey, USA, April 21, 2026 In a major regulatory advancement for rare disease therapeutics, Polaryx Therapeutics, Inc....
Immutep Secures FDA Orphan Status for Efti in Sarcoma
Sydney, Australia | April 15, 2026 Immutep Limited has achieved a significant regulatory milestone with the U.S. Food and...
Jazz Pharmaceuticals Presents Neurology Drug Data at AAN
DUBLIN, Ireland, April 9, 2026 Jazz Pharmaceuticals plc has announced the presentation of six scientific abstracts, including one oral...
Advertisements
Immutrin Raises $87M to Advance Amyloidosis Antibody Therapy
CAMBRIDGE, UK, April 8, 2026 Immutrin Ltd has successfully raised £65 million ($87 million) in an oversubscribed Series A...
ALS Research at Risk from Proposed FY27 Budget Cuts
ARLINGTON, Virginia, United States, April 7, 2026 The ALS Association has issued a strong statement warning that the proposed...
Biogen to Acquire Apellis in $5.6B Strategic Pharma Deal
CAMBRIDGE, Mass. & WALTHAM, Mass., USA — March 31, 2026 In a major biopharmaceutical industry consolidation, Biogen Inc. has...
Recordati Confirms CVC Interest in Major Pharma M&A Deal
MILAN, Italy, March 26, 2026 Recordati S.p.A. has confirmed receiving a non-binding indication of interest from CVC Capital Partners...
IMCIVREE Gains EU Momentum for Rare Obesity Disorder
Boston, March 26, 2026 In a significant advancement for rare disease therapeutics, Rhythm Pharmaceuticals has received a positive opinion...
Advertisement
